Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SPDR Series Trust SPDR S&P Biotech ETF (NY:XBI)

80.59 +2.43 (+3.11%)
Official Closing Price Updated: 8:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,203,044
Open 77.71
Bid (Size) 77.00 (42)
Ask (Size) 77.25 (5)
Prev. Close 78.16
Today's Range 77.34 - 80.87
52wk Range 77.34 - 105.47
Shares Outstanding 625,000
Dividend Yield 0.04%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biotech Stocks Dive After Trump Tacks On 20% European Tariff. Why AbbVie, Merck Could Be Exposed.
It's unclear whether pharmaceutical goods could be exempt from tariffs. A number of drugmakers manufacture ingredients abroad. 
Via Investor's Business Daily
Topics Economy Government World Trade
Exposures Political Supply Chain Tariff
Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies
The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy. 
Via Stocktwits
Topics ETFs Government
Exposures COVID-19 Political Product Safety

Performance

YTD
-12.0%
-12.0%
1 Month
-5.9%
-5.9%
3 Month
-12.0%
-12.0%
6 Month
-17.8%
-17.8%
1 Year
-11.1%
-11.1%

More News

Read More
Biotech Stocks Take Another Beating As 'Chaos' Reigns At FDA With Reports Of Mass Firings
Via Investor's Business Daily
Topics Workforce
Exposures COVID-19 Layoff Product Safety
Moderna, Novavax Shares Are Tumbling Monday: What's Going On?
Via Benzinga
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
Via Investor's Business Daily
Exposures Product Safety
Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks
Via Stocktwits
Exposures Product Safety
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up
Via Stocktwits
Capricor Therapeutics Stock Surges After Q4 Results Beat Estimates: Retail Gets More Bullish
Via Stocktwits
Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon
Via Stocktwits
Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss
Via Stocktwits
Healthcare Stocks Doing Well But SMID Biotech Looking A Little Frazzled
Via Talk Markets
Topics ETFs Stocks / Equities
SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?
Via Stocktwits
Healthcare Sector Trying To Bounce Back
Via Talk Markets
Topics ETFs Stocks / Equities
Capricor Therapeutics’ Retail Chatter Explodes On Stocktwits After FDA Grants Priority Review For DMD Therapy
Via Stocktwits
Exposures Product Safety
Is It Time To Shift Focus To Beaten-Down Healthcare Stocks As Volatility Soars?
Via Talk Markets
Topics ETFs Stocks / Equities
Biotech Rally Coming In Weeks Ahead?
Via Talk Markets
Topics ETFs Stocks / Equities
Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing
Via Stocktwits
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook
Via Stocktwits
Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week
Via Stocktwits
Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print
Via Stocktwits
Exposures Product Safety
MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’
Via Stocktwits
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally
Via Stocktwits
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
Via Benzinga
Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism
Via Stocktwits
SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect
Via Stocktwits

Frequently Asked Questions

Is SPDR Series Trust SPDR S&P Biotech ETF publicly traded?
Yes, SPDR Series Trust SPDR S&P Biotech ETF is publicly traded.
What exchange does SPDR Series Trust SPDR S&P Biotech ETF trade on?
SPDR Series Trust SPDR S&P Biotech ETF trades on the New York Stock Exchange
What is the ticker symbol for SPDR Series Trust SPDR S&P Biotech ETF?
The ticker symbol for SPDR Series Trust SPDR S&P Biotech ETF is XBI on the New York Stock Exchange
What is the current price of SPDR Series Trust SPDR S&P Biotech ETF?
The current price of SPDR Series Trust SPDR S&P Biotech ETF is 80.59
When was SPDR Series Trust SPDR S&P Biotech ETF last traded?
The last trade of SPDR Series Trust SPDR S&P Biotech ETF was at 04/02/25 08:00 PM ET
What is the market capitalization of SPDR Series Trust SPDR S&P Biotech ETF?
The market capitalization of SPDR Series Trust SPDR S&P Biotech ETF is 50.37M
How many shares of SPDR Series Trust SPDR S&P Biotech ETF are outstanding?
SPDR Series Trust SPDR S&P Biotech ETF has 50M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.